ReviewJournal of investigative medicine : the official publication of the American Federation for Clinical Research2016
Targeting hypoxia in inflammatory bowel disease.
Review in Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Metabolic host-microbe crosstalk in stabilization of epithelial HIF.Microbiome · 2026Article
- Article
- Expression of the cobalamin transporters cubam and MRP1 in the canine ileum-Upregulation in chronic inflammatory enteropathy.PloS one · 2024Article
- Transcriptome and 16S rRNA Analyses Reveal That Hypoxic Stress Affects the Antioxidant Capacity of Largemouth Bass (Antioxidants (Basel, Switzerland) · 2022Article
- Inhibition of hypoxia-inducible factor-prolyl hydroxylation protects from cyclophosphamide-induced bladder injury and urinary dysfunction.American journal of physiology. Renal physiology · 2022Article
- The Host-Microbiome Response to Hyperbaric Oxygen Therapy in Ulcerative Colitis Patients.Cellular and molecular gastroenterology and hepatology · 2022Article
- Butyrate Protects Porcine Colon Epithelium from Hypoxia-Induced Damage on a Functional Level.Nutrients · 2021Article
- Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience.Advances in chronic kidney disease · 2019Review
- Hypoxia and Inflammation in Cancer, Focus on HIF and NF-κB.Biomedicines · 2017Review
- Pathobiology of neutrophil-epithelial interactions.Immunological reviews · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
In this review, I summarize some of the recent insight into pharmacological targeting of hypoxia in disease models. Studies from cultured cell systems, animal models, and translation to human patients have revealed that posttranslational modifications of individual proteins within NF-κB and hypoxia-inducible factor pathways serve as ideal targets for analysis in disease models. Studies defining differences and similarities between these responses have taught us a number of important lessons about the complexity of the inflammatory response. A clearer definition of these pathways has provided new insight into disease pathogenesis and, importantly, the potential for new therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.